MICHAEL J O'NEILL

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint AMPA receptor potentiators: application for depression and Parkinson's disease
    MICHAEL J O'NEILL
    Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, UK
    Curr Drug Targets 8:603-20. 2007
  2. doi request reprint N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link betw
    Matthew J Fell
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC0510, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 336:165-77. 2011
  3. pmc Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease
    Paulien Gm Ravenstijn
    Division of Pharmacology, LACDR Leiden University, Leiden, The Netherlands
    Fluids Barriers CNS 9:4. 2012
  4. ncbi request reprint Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease
    MICHAEL J O'NEILL
    Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
    Eur J Pharmacol 486:163-74. 2004
  5. ncbi request reprint AMPA receptor potentiators as cognitive enhancers
    MICHAEL J O'NEILL
    Eli Lilly and Co Ltd, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK
    IDrugs 10:185-92. 2007
  6. ncbi request reprint The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration
    M J O'Neill
    Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
    Curr Drug Targets CNS Neurol Disord 1:399-411. 2002
  7. ncbi request reprint SMi 4th Annual Conference on Neurodegenerative Disorders: a focus on Alzheimer's and Parkinson's disease
    MICHAEL J O'NEILL
    Eli Lilly and Co Ltd, Erl Wood Manor, Windlesham, Surrey, UK
    Expert Opin Investig Drugs 13:1369-73. 2004
  8. ncbi request reprint LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease
    MICHAEL J O'NEILL
    Eli Lilly and Co, Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK
    CNS Drug Rev 11:77-96. 2005
  9. ncbi request reprint AMPA receptor potentiators for the treatment of CNS disorders
    MICHAEL J O'NEILL
    Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
    Curr Drug Targets CNS Neurol Disord 3:181-94. 2004
  10. ncbi request reprint LY393615, a novel neuronal Ca(2+) and Na(+) channel blocker with neuroprotective effects in models of in vitro and in vivo cerebral ischemia
    M J O'Neill
    Lilly Research Centre Ltd, Erl Wood Manor, Windlesham, GU20 6PH, Surrey, UK
    Brain Res 888:138-149. 2001

Collaborators

Detail Information

Publications35

  1. ncbi request reprint AMPA receptor potentiators: application for depression and Parkinson's disease
    MICHAEL J O'NEILL
    Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, UK
    Curr Drug Targets 8:603-20. 2007
    ..The present review summarises studies into the effects of AMPA receptor potentiators (with a focus on the biarylpropylsulfonamides) in rodent models of depression and Parkinson's disease...
  2. doi request reprint N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link betw
    Matthew J Fell
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC0510, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 336:165-77. 2011
    ..In addition, we provide evidence that sleep EEG and CSF t-MeHA might function as viable biomarker approaches to facilitate the translational development of THIIC and other mGlu2 potentiators...
  3. pmc Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease
    Paulien Gm Ravenstijn
    Division of Pharmacology, LACDR Leiden University, Leiden, The Netherlands
    Fluids Barriers CNS 9:4. 2012
    ..abstract:..
  4. ncbi request reprint Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease
    MICHAEL J O'NEILL
    Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
    Eur J Pharmacol 486:163-74. 2004
    ..Therefore, we propose that AMPA receptor potentiators offer the potential of a new therapy to halt the progression and perhaps repair the degeneration in Parkinson's disease...
  5. ncbi request reprint AMPA receptor potentiators as cognitive enhancers
    MICHAEL J O'NEILL
    Eli Lilly and Co Ltd, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK
    IDrugs 10:185-92. 2007
    ..Nevertheless, boosting Ca(2+) flux through the AMPA receptor, and enhancing LTP and downstream pathways may provide a novel approach to the treatment of cognitive deficits...
  6. ncbi request reprint The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration
    M J O'Neill
    Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
    Curr Drug Targets CNS Neurol Disord 1:399-411. 2002
    ....
  7. ncbi request reprint SMi 4th Annual Conference on Neurodegenerative Disorders: a focus on Alzheimer's and Parkinson's disease
    MICHAEL J O'NEILL
    Eli Lilly and Co Ltd, Erl Wood Manor, Windlesham, Surrey, UK
    Expert Opin Investig Drugs 13:1369-73. 2004
    ..g., glial cell line-derived neurotrophic factor) and mixed lineage/c-Jun N-terminal kinase inhibitors, such as CEP-1347. Small molecules that enhance endogenous signalling and repair pathways were also discussed...
  8. ncbi request reprint LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease
    MICHAEL J O'NEILL
    Eli Lilly and Co, Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK
    CNS Drug Rev 11:77-96. 2005
    ..Therefore, we propose that AMPA receptor potentiators such as LY503430 offer the potential of a new disease modifying therapy for Parkinson's disease...
  9. ncbi request reprint AMPA receptor potentiators for the treatment of CNS disorders
    MICHAEL J O'NEILL
    Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
    Curr Drug Targets CNS Neurol Disord 3:181-94. 2004
    ....
  10. ncbi request reprint LY393615, a novel neuronal Ca(2+) and Na(+) channel blocker with neuroprotective effects in models of in vitro and in vivo cerebral ischemia
    M J O'Neill
    Lilly Research Centre Ltd, Erl Wood Manor, Windlesham, GU20 6PH, Surrey, UK
    Brain Res 888:138-149. 2001
    ..The compound is neuroprotective when administered post-occlusion and may therefore be a useful anti-ischaemic agent...
  11. ncbi request reprint ARL 17477, a selective nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia
    M J O'Neill
    Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, GU20 6PH, Surrey, UK
    Brain Res 871:234-44. 2000
    ....
  12. ncbi request reprint LY377770, a novel iGlu5 kainate receptor antagonist with neuroprotective effects in global and focal cerebral ischaemia
    M J O'Neill
    Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham, GU20 6PH, Surrey, UK
    Neuropharmacology 39:1575-88. 2000
    ..LY377770 is a novel, soluble, systemically active iGlu5 antagonist with efficacy in global and focal ischaemia, even when administered post-occlusion. LY377770 may therefore be useful as a neuroprotectant in man...
  13. ncbi request reprint Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia
    M J O'Neill
    Lilly Research Centre, Eli Lilly and Co Ltd, Windlesham, UK
    Neuropharmacology 37:1211-22. 1998
    ..LY377770 (a mixed AMPA/iGluR5 antagonist and active isomer of LY294486) demonstrated good neuroprotection with a 2-h time window and may therefore be useful in the treatment of ischaemic conditions...
  14. ncbi request reprint Neuroprotective effects of the antioxidant LY231617 and NO synthase inhibitors in global cerebral ischaemia
    M J O'Neill
    Lilly Research Centre Limited, Erl Wood Manor, Surrey, UK
    Brain Res 760:170-8. 1997
    ..Antioxidants such as LY231617 or neuronal NO synthase inhibitors can prevent the ischaemia-induced neurodegeneration and may be useful as anti-ischaemic agents...
  15. ncbi request reprint LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease
    Tracey K Murray
    Eli Lilly and Co Ltd, Lilly Research Centre, Surrey, UK
    J Pharmacol Exp Ther 306:752-62. 2003
    ..Therefore, we propose that AMPA receptor potentiators offer the potential of a new disease modifying therapy for Parkinson's disease...
  16. ncbi request reprint Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease
    Tracey K Murray
    Lilly Research Centre, Eli Lilly and Co Ltd, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
    Pharmacol Biochem Behav 73:455-66. 2002
    ..These data suggest that activation of Group II mGlu receptors can provide some protection in models of PD, while their role in providing functional improvement is less clear...
  17. ncbi request reprint Neuroreplacement, growth factor, and small molecule neurotrophic approaches for treating Parkinson's disease
    MICHAEL J O'NEILL
    Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Windlesham Surrey GU20 6PH, United Kingdom
    Int Rev Neurobiol 77:179-217. 2007
  18. pmc Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator
    Fran├žois Gastambide
    Lilly Centre for Cognitive Neuroscience, Lilly Research Laboratories, Eli Lilly and Co Ltd, Windlesham, UK
    Neuropsychopharmacology 37:1057-66. 2012
    ..This study also illustrates the importance of studying putative cognitive enhancing drug effects in a number of models which may have implications for the future development of the compound...
  19. ncbi request reprint Amphetamine promotes task-dependent recovery following focal cortical ischaemic lesions in the rat
    Gary Gilmour
    Eli Lilly and Co Ltd, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
    Behav Brain Res 165:98-109. 2005
    ..They also demonstrate that different behavioural tasks measuring superficially similar behavioural outputs may show different sensitivities to such drug effects...
  20. ncbi request reprint Neuroprotective effects of 7-nitroindazole in the gerbil model of global cerebral ischaemia
    M J O'Neill
    Lilly Research Centre Limited, Surrey, UK
    Eur J Pharmacol 310:115-22. 1996
    ..These results indicate that nitric oxide plays a role in ischaemic cell death and that selective neuronal nitric oxide synthase inhibitors can protect against ischaemic brain damage...
  21. ncbi request reprint A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders
    Jeffrey M Witkin
    Psychiatric Drug Discovery, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 0510, USA
    Trends Pharmacol Sci 26:609-17. 2005
    ..Thus, CB1 receptor antagonism might constitute an integrated pharmacotherapeutic approach that impacts the affective, cognitive, appetitive and motivational neuronal networks involved in mood disorders...
  22. ncbi request reprint NAALADase (GCP II) inhibition prevents cocaine-kindled seizures
    Jeffrey M Witkin
    Drug Development Group, Addiction Research Center, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA
    Neuropharmacology 43:348-56. 2002
    ..Similarly, acutely-administered 2-PMPA did not block cocaine seizures in fully-kindled mice. NAALADase inhibition thus provides a novel means of attenuating the development of cocaine seizure kindling...
  23. ncbi request reprint Some contextual and historical determinants of the effects of chlordiazepoxide on punished responding of rats
    Jeffrey M Witkin
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 0510, USA
    Psychopharmacology (Berl) 163:488-94. 2002
    ..Nonetheless, the necessary and sufficient conditions for the anxiolytic-like activity in this animal model have not been fully delineated...
  24. doi request reprint Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression
    Donald R Gehlert
    Neuroscience and Endocrine Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 329:429-38. 2009
    ..Thus, GW803430 produces robust antiobesity and antidepressant-like effects in rats and mice at doses that compete for central MCHR1 in vivo. As such, MCHR1 should be considered as a promising target for future drug discovery efforts...
  25. ncbi request reprint A parametric analysis of punishment frequency as a determinant of the response to chlordiazepoxide in the Vogel conflict test in rats
    Scott D Gleason
    Neuroscience Discovery Research, The Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Pharmacol Biochem Behav 87:380-5. 2007
    ..Parametric variation under the Vogel conflict test may be useful in comparing the efficacy of novel approaches to the treatment of anxiety disorders...
  26. ncbi request reprint Enhancement of antidepressant potency by a potentiator of AMPA receptors
    Xia Li
    Neuroscience Discovery Research, Eli Lilly and Co, Lilly Research Laboratories, Corporate Center, Indianapolis, Indiana, USA
    Cell Mol Neurobiol 23:419-30. 2003
    ....
  27. ncbi request reprint Constitutive deletion of the serotonin-7 (5-HT(7)) receptor decreases electrical and chemical seizure thresholds
    Jeffrey M Witkin
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Epilepsy Res 75:39-45. 2007
    ..In addition, the data suggest that the lower thresholds for seizures produced by diverse mechanisms should be taken into account when interpreting other aspects of the phenotype and behavioral pharmacology of this mouse...
  28. ncbi request reprint Metabotropic glutamate receptors in the control of mood disorders
    Jeffrey M Witkin
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    CNS Neurol Disord Drug Targets 6:87-100. 2007
    ....
  29. ncbi request reprint In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders
    Linda M Rorick-Kehn
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC0510, Indianapolis, IN 46285, USA
    Psychopharmacology (Berl) 193:121-36. 2007
    ....
  30. ncbi request reprint A rapid punishment procedure for detection of anxiolytic compounds in mice
    Jeffrey M Witkin
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 0510, USA
    Psychopharmacology (Berl) 172:52-7. 2004
    ..The use of mice in these tests has been limited, but the utility of this species in drug discovery and for neurobiological inquiry would benefit from a rapid, reliable method...
  31. ncbi request reprint Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice
    Xia Li
    Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285 0510, USA
    J Pharmacol Exp Ther 319:254-9. 2006
    ..This mechanism may not only provide a novel approach to the therapeutic management of depressive disorders but also may be useful in the augmentation of effects of traditional antidepressant agents...
  32. ncbi request reprint Long-term restorative effects of bromocriptine on operant responding in the 6-hydroxydopamine-lesioned rat
    Ellen M Murphy
    aBrain Repair Group, School of Biosciences bSchool of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff cEli Lilly and Co Ltd, Surrey, UK
    Neuroreport 24:1019-24. 2013
    ..2 mg/kg). These results may reflect a conditioning effect of bromocriptine on operant behaviour. ..
  33. ncbi request reprint Alterations in hippocampal excitability, synaptic transmission and synaptic plasticity in a neurodevelopmental model of schizophrenia
    Thomas M Sanderson
    Centre for Cognitive Neuroscience, Eli Lilly and Co, Erl Wood Manor, Windlesham GU20 6PH, UK
    Neuropharmacology 62:1349-58. 2012
    ..These findings suggest that delivering neurodevelopmental insults at E17 may offer insights into some of the physiological alterations that underlie behavioural and cognitive symptoms observed in schizophrenia...
  34. ncbi request reprint A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity
    Zeshan Ahmed
    Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK
    Acta Neuropathol 127:667-83. 2014
    ..The rapid and robust propagation of tau pathology in this model will be valuable for both basic research and the drug discovery process...
  35. pmc The methylazoxymethanol acetate (MAM-E17) rat model: molecular and functional effects in the hippocampus
    Eva Hradetzky
    Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK
    Neuropsychopharmacology 37:364-77. 2012
    ..Thus, this study provides the first molecular evidence, combined with functional validation, that the MAM-E17 rat model reproduces hippocampal deficits relevant to the pathology of schizophrenia...